Replies to post #452441 on NorthWest Biotherapeutics Inc (NWBO)

[The Danish Dude]

Thanks for info dennisdave!

[H2R]

Thanks dennisdave!

That's quite encouraging.

Cheers!

[exwannabe]

My message is. They are far in the MHRA process and in the near future,

And again, if they are far in the process why has OHEAG not discussed it?

You have zero basis for your assertion, and there is plenty of reason to doubt it.

[meirluc]

Thank you very much Dennisdave for the clarification.

However, information about difficulties with the publication and postponing it after TLD and MHRA approval, seems to me to be Material information and I am somewhat dismayed that this would leek out.

Not at all the tight lip pattern that NWBO has been following for so many years.

Having said that, it does make sense that MHRA would only permit DCVax-L to be produced because MHRA has ample proof about the vaccine's efficacy.

[biosectinvestor]

Thanks Dennis Dave. I believe that also to be the case Re the UK Specials program sales, it’s not possible if the RA knows they have a failed drug. Allowing a company to sell such a drug at $200,000 out of pocket, to dying patients, a drug that had failed? To stop exactly that kind of exploitation is the most basic purpose and function of all the drug regulators, not the least MHRA and FDA. More than my “belief”, I feel certain they would stop anything so exploitative if the facts were as shorts suggest. That letter would be great.

[newman2021]

Thanks DD for sharing. Great maneuver by LG et al.

[Poor Man -]

That they can’t get a journal article accepted is stunning given how they sold the importance of the publication to investors.

Just stunning.

[flipper44]

Ignoring the rest of your post because I don’t trust Les (joe Isuzu) Goldman, (let alone his stinking hearsay) the last paragraph you wrote makes no sense. NWBO is not currently producing commercial DCVax-l, they are doing it for specials. I mean your point is, with all due respect, useless. I hope the people persuaded by your post take a second more critical look.